Mazdutide
LY3305677 · IBI362
Innovent GLP-1/glucagon dual agonist (IBI362). China Phase 3 GLORY numbers are large. Not FDA-approved as of this catalog date. Not tirzepatide and not retatrutide.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Metabolic / weight7.5/10
China Phase 3 GLORY obesity readouts. Ceiling 8 for Phase 2–3. Haircut: not a US label, and a research vial is not trial material.
Compound card
- Sequence
- Long-acting GLP-1/glucagon dual agonist (IBI362 / LY3305677)
- Class
- Once-weekly dual agonist (Innovent; not FDA-approved as of this review)
- Formula
- Long-acting GLP-1/glucagon dual peptide
- Status
- Not FDA-approved · research use
How it works
Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist (GCGr/GLP-1R) developed by Innovent Biologics. It combines GLP-1 agonism (appetite suppression, insulin secretion) with glucagon receptor agonism (increased hepatic fatty acid oxidation and energy expenditure) - the same glucagon-adding mechanism that makes retatrutide so potent. Phase 3 GLORY trials reported up to 18.6% body weight reduction at 9 mg over 48 weeks in Chinese patients with obesity.
Source: PMID: 37578886
Research Use Cases
- ✓Obesity / Weight Management: High
- ✓Metabolic Liver Disease (MASH): Emerging
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Escalation | 3 mg → 6 mg → 9 mg | Once weekly (SC) | Phase 3 GLORY protocol: escalate every 4 weeks. 9 mg target dose. |
Administration
Timeline
Who it is for
Obesity / Weight Management
HighPhase 3: 18.6% BWL at 9 mg over 48 weeks. Approved in China 2024; global regulatory submission pending.
Metabolic Liver Disease (MASH)
EmergingGlucagon receptor agonism reduces hepatic fat accumulation - early trial signals.
Reconstitution
| Vial | Water | Concentration | Example dose |
|---|---|---|---|
| 6 mg research/compounded cake | 2.0 mL BAC | 3 mg/mL | 3 mg = 1.0 mL = 100 units on a U-100. This is not GLORY trial supply. |
Change vial size or water volume? Open the reconstitution calculator.
Safety & Considerations
Approved in China (2024) for obesity. Not FDA-approved. GI side effects consistent with GLP-1 class. Investigation ongoing in global Phase 3 trials.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- GLORY describes trial product in a specific population, not a 6 mg cake.
- Glucagon agonism is extra energy-expenditure language and extra monitoring (HR, glycogen, lean mass).
- Not interchangeable with tirzepatide (GIP/GLP-1) or retatrutide (triple).
Verdict
Mazdutide is a GLP-1 plus glucagon dual agonist in Innovent’s China program. Phase 3 numbers are large. It is not Zepbound and not a US pen on this leaf’s date. Gray-market “mazdutide” is unverified identity.
Interactions & Contraindications
Approved in China (2024) for obesity. Not FDA-approved. GI side effects consistent with GLP-1 class. Investigation ongoing in global Phase 3 trials.
Frequently Asked Questions
Is mazdutide approved in the US?▼
How does mazdutide compare to tirzepatide?▼
References
- Ji L et al. “"Mazdutide (IBI362) in Chinese adults with obesity (GLORY-1)".” The Lancet Diabetes & Endocrinology (2024).
📚 Related Articles
Looking for a trusted source? See our recommended suppliers
Independently tested · COA-verified · Save 10% with our exclusive code